#United States #ITF Therapeutics #Concord #Duchenne Muscular Dystrophy #givinostat

ITF Therapeutics LLC Shares New Findings on Givinostat for DMD

ITF Therapeutics LLC, the American branch of Italfarmaco dedicated to treating rare diseases, has recently provided compelling insights into Givinostat. These were presented at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference held from March 8 to March 11. The conference showcased ten abstracts that delve into the long-term effects and safety profile of Givinostat in patients diagnosed with Duchenne Muscular Dystrophy (DMD).

One of the central themes was the ongoing discussions surrounding Givinostat's potential to alter the trajectory of DMD's progression, which can lead to severe mobility issues and muscle degeneration. Long-term study results indicate an encouraging safety profile, as Givinostat was administered to individuals who are part of an open-label extension study following earlier randomized trials. The findings included critical data reflecting on muscle contractile areas and a notable delay in the age at which patients typically experience loss of ambulation.

Scott Baver, Ph.D., Vice President and Head of Global Medical Affairs at Italfarmaco, emphasized the importance of these findings, stating, “The data shared during this significant conference underscores our ongoing commitment to enhancing the understanding of Givinostat treatment in DMD patients.” By investigating safety and efficacy metrics comprehensively, the team aims to empower families and healthcare professionals to make informed decisions regarding the treatment options available for DMD.

Among the various findings presented, there were key posters that highlighted:

• - Long-Term Safety Evaluate: An interim safety analysis from the open-label extension study provided critical safety insights for those who had previously participated in Givinostat studies. This helps establish a solid foundation for expectations regarding the drug's long-term use.

• - Reduction in Muscle Decline: Data indicating that Givinostat reduces the decline in muscle contractile area, as well as decreases fat infiltration in muscle tissues, were significant. Using precise measures such as contractile cross-sectional area (cCSA) and fat fraction through advanced imaging techniques, researchers analyzed the impact of Givinostat on functional muscle tissue.

• - Delay in Ambulatory Loss: Additional findings suggested that prolonged treatment with Givinostat, especially when coupled with standard care corticosteroids, shows a potential delay in the loss of ambulation in patients older than six. This analysis included a broader patient base and extended follow-up, crucial for assessing the drug's efficacy.

• - Reprogramming Fibrosis in DMD Cells: Exploring the biochemical mechanisms, one study indicated how Givinostat might influence the fibrotic response in muscle cells within DMD patients, showcasing its potential in addressing underlying pathophysiological processes.

As highlighted by Dr. Aravindhan Veerapandiyan from the University of Arkansas, these findings reinforce the vital importance of extended follow-ups and comprehensive data evaluations in shaping personalized treatment approaches for individuals suffering from DMD.

About Givinostat

Givinostat, branded as DUVYZAT, is a histone deacetylase inhibitor approved by the FDA for treating DMD in patients aged six and older. The mechanism of action involves mitigating the overactivity of HDAC enzymes that contribute to chronic inflammation in muscle tissues, thus fostering enhanced muscle repair and reducing chronic degeneration associated with DMD.

For more detailed information regarding DUVYZAT, clinicians and interested individuals can visit DUVYZAT.com.

ITF Therapeutics Overview

Established in January 2024, ITF Therapeutics aims to develop tailored treatment solutions for rare diseases through stringent research and collaboration with patient advocacy groups. This commitment fuels their mission to bring innovative and impactful therapies to communities affected by these challenging conditions. Learn more about their work and insights at itftherapeutics.com